摘要
目的探索血浆基质金属蛋白酶-2(MMP-2)在ST段抬高性心肌梗死(STEMI)患者中的表达情况,及对近期主要不良心血管事件(MACE)的预测价值。方法连续入选2013年9月~2015年9月完全符合诊断标准的STEMI患者110例,另选取健康志愿者100例作为对照组。用酶联免疫吸附试验(ELISA)检测血浆MMP-2水平,计算患者出院GRACE评分。记录一般临床资料及出院后6个月内MACE事件发生情况。结果 STEMI患者MMP-2水平较对照组明显升高[(183.47±46.51)ng/ml vs.(66.26±26.73)ng/ml],差异具有统计学意义(P<0.05);STEMI患者出院后6个月时间内,发生MACE事件者34人,MACE组MMP-2和GRACE评分均高于非MACE组,差异具有统计学意义(P均<0.05);使用受试者工作特征曲线(ROC)分析GRACE评分、MMP-2水平预测STEMI患者6个月内发生MACE的AUC分别为0.711(95%CI:0.565~0.856,P=0.013)和0.737(95%CI:0.601~0.873,P=0.005)。结论 MMP-2对STEMI患者近期发生MACE事件有一定的预测价值。
Objective To study the plasma matrix metalloproteinase-2(MMP-2)in ST segment elevation myocardial infarction(STEMI)patients to observe the expression of registry of acute coronary events(GRACE)changes in plasma MMP-2 score,effect of MMP-2 on prevention of adverse cardiovascular events.Methods From September 2013 to September 2015,110STEMI patients(STEMI group)and 100 healthy persons(control group)were selected.Plasma MMP-2 index were measured by ELISA assay.The patient's GRACE score was calculated.General clinical data and MACE events within 6 months after discharge were recorded.Results The level of MMP-2 in STEMI patients was significantly higher than that in the control group[(183.47±46.51)ng/ml vs.(66.26±26.73)ng/ml],the difference was statistically significant(P<0.05).In 6 months after discharge from STEMI,34 patients developed MACE,and MMP-2 and GRACE scores in MACE group were significantly higher than those in non-MACE group(all P<0.05).The area under the curve of MACE predicted by GRACE score and MMP-2 level in 6 months after STEMI were 0.711(95%CI:0.565~0.856,P=0.013)and 0.737(95%CI:0.601~0.873,P=0.005).Conclusion MMP-2 has some predictive value for the recent occurrence of MACE in STEMI patients.
作者
庹田
郭俊林
Tuo Tian;Guo Junlin(Department of Cardiology,Guang'an City people's hospital,Guang'an Sichuan 638000)
出处
《中国循证心血管医学杂志》
2018年第3期297-299,303,共4页
Chinese Journal of Evidence-Based Cardiovascular Medicine
基金
四川省医学会科研课题计划(S15031)
